14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TTI vs HHS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Harte Hanks, Inc. (HHS) captures the overall head-to-head institutional edge over TETRA Technologies, Inc. (TTI) on higher Unified Composite conviction (61.8/100 BUY vs. 35.2/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while TTI wins 4–1 across the 6-pillar growth and valuation breakdown. TTI trades at $6.20 (21.3x Forward P/E, 7.4% operating margin) versus HHS at $3.85 (14.3x Forward P/E, -3.2% operating margin).
Growth vs. Quality Trade-Off: HHS earns the overall head-to-head edge with a stronger Unified Composite Score (61.8/100 BUY vs. TTI 35.2/100 SELL) and 0.49β · 46% Vol risk profile, whereas TTI leads top-line expansion (+9.6% YoY revenue growth, 1.82x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TTI vs HHS. Trailing 12-month operating profitability (TTI 7.4% vs HHS -3.2%) and valuation multiples (TTI 21.3x vs HHS 14.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Conglomerates value chain with $30.0M market capitalization and -3.2% operating margin.
OpEx & R&D Reinvestment19.3% of Rev ($30M)
90D Engineering Disclosures0 Published
Investor FAQ TTI vs HHS Key Questions & Quantitative Answers
As of Nov 16, 2026, Harte Hanks, Inc. (HHS) captures the overall head-to-head institutional edge over TETRA Technologies, Inc. (TTI) on higher Unified Composite conviction (61.8/100 BUY vs. 35.2/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while TTI wins 4–1 across the 6-pillar growth and valuation breakdown. TTI trades at $6.20 (21.3x Forward P/E, 7.4% operating margin) versus HHS at $3.85 (14.3x Forward P/E, -3.2% operating margin). Growth vs. Quality Trade-Off: HHS earns the overall head-to-head edge with a stronger Unified Composite Score (61.8/100 BUY vs. TTI 35.2/100 SELL) and 0.49β · 46% Vol risk profile, whereas TTI leads top-line expansion (+9.6% YoY revenue growth, 1.82x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
TTI leads the Growth & Scale pillar: TTI posts +9.6% YoY revenue growth and +54.0% YoY earnings growth on $657M TTM revenue (28.8% gross margin, 7.4% operating margin), compared with HHS at -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin). On trailing 12-month operating scale, TTI generates $657M in USD-normalized revenue versus $155M for HHS. In operating R&D and SG&A reinvestment, TTI deploys 21.4% of Rev ($140M) (0 90-day corporate R&D disclosures) versus 19.3% of Rev ($30M) (0 disclosures) for HHS.
HHS screens cheaper on headline valuation multiples. TTI trades at 21.3x Forward P/E, 91.0x Trailing P/E, 1.82x PEG, and 1.4x EV/Revenue (13.2% EBITDA margin), whereas HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TTI (2.9% ROE) versus HHS (-30.4% ROE) capital efficiency.
In options market volatility and institutional positioning, TTI carries 57.2% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.45β · 61% Vol realized risk). By comparison, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.